Q32 Bio (QTTB) Equity Income (2022 - 2024)
Q32 Bio's quarterly Equity Income came in at -$1.4 million in Q2 2024, down 723.3% quarter-over-quarter from -$176000.0 in Q1 2024.
Q32 Bio has reported Equity Income for 2 years, with the latest figure at -$1.4 million in Q2 2024.
- For the quarter ending Q2 2024, Equity Income changed N/A year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2025 stood at -$1.4 million (down 723.3% YoY), and the FY2024 full-year result was -$1.6 million, changed N/A from the prior year.
- Equity Income for Q2 2024 stood at -$1.4 million, down from -$176000.0 in the prior quarter.
- The five-year high for Equity Income was -$176000.0 in Q1 2024, with the low at -$2.2 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.45 Mn |
| Mar 31, 2024 | -176,000.00 |
| Sep 30, 2022 | -2.18 Mn |
| Jun 30, 2022 | -1.36 Mn |
| Mar 31, 2022 | -591,000.00 |